One in eight new cancer cases this year trace back to infections that we already know how to prevent or treat.
Story Snapshot
- IARC estimates 2.3 million new cancers in 2024 are linked to infections.
- Five pathogens drive most cases: H. pylori, HPV, hepatitis B, Epstein–Barr virus, and hepatitis C.
- Burden falls hardest on Eastern Asia and sub-Saharan Africa, where access gaps persist.
- Vaccines, screening, and simple treatment could cut large shares of these cancers.
What the new estimate says, in plain numbers
The International Agency for Research on Cancer, part of the World Health Organization, reported that infections account for about 12 percent of all new cancer cases in 2024, or 2.3 million people worldwide. The study appears in The Lancet Oncology and draws on the agency’s Global Cancer Observatory. The estimate groups cancers linked to a short list of known infectious agents. That list spans viruses, a bacterium, and a parasite category used in earlier updates.
Five agents explain the bulk of the total. Helicobacter pylori, a stomach bacterium, is linked to about 760,000 cancers. Human papillomavirus accounts for about 750,000 cases, mainly cervical cancer. Hepatitis B virus is tied to about 360,000 cases, Epstein–Barr virus to about 260,000, and hepatitis C virus to about 160,000. These figures align with long-standing science on how chronic infection triggers cell damage over time. The agency describes them as preventable targets, not random strikes.
Where the burden lands, and why that matters
Regions with fewer resources carry the heaviest load. IARC and independent reports say Eastern Asia and sub-Saharan Africa see the highest infection-linked shares. The reasons are not a mystery: gaps in vaccination, screening, and access to simple antimicrobial treatment push risk up. The share in higher income regions is notably lower, which tracks with better uptake of hepatitis B and human papillomavirus vaccines and broader screening.
These differences shape policy choices. A health minister in a lower income country does not need a moonshot to make gains. They need steady rollout of hepatitis B vaccination at birth, catch-up programs for teens, human papillomavirus vaccination for girls and boys, cervical screening, and low-cost testing and treatment for Helicobacter pylori. Each step chips away at a known causal chain. That is conservative common sense: fix what is proven and prevent what is predictable.
How the estimate was built, and what it means for you
IARC uses a standard approach called the population attributable fraction. The method asks a clear question: if we removed a known infection, how many cancer cases would likely not occur? The team multiplies cancer incidence by the fraction tied to each infection, based on established links. The result is a model-based estimate, not a file of individual lab results. But for planning prevention at scale, this is the right tool, and it has been refined across updates since at least 2008.
For people asking what to do now, the guidance is direct. Ask your doctor about human papillomavirus vaccination for your kids and, if recommended, for you. Confirm hepatitis B vaccination status. If you live in or come from regions with higher stomach cancer rates, ask about testing and treatment for Helicobacter pylori. If you have risk factors for hepatitis C, get tested and treated. These are not exotic steps. They are routine medicine that prevents real cancers.
The long arc: steady science, steady wins
This update fits a pattern. IARC’s estimates have moved from about 16 percent of cancers in 2008, to 13 percent in 2018, to about 12 percent in 2024. The direction reflects vaccine rollouts, treatment access, and screening, not a sudden change in biology. The consistent regional gradient also remains. Sub-Saharan Africa and parts of Asia still face higher shares than high-income regions, which shows where prevention will save the most lives first.
The practical takeaway is simple. We do not need a grand new theory to cut these cancers. We need to finish the jobs already in hand: vaccinate, screen, test, treat, and follow up. Budgets are tight everywhere, but thrift argues for moves that avert costly disease later. When an infection is a known spark, snuff it out early. That is how a dry statistic—one in eight—becomes a shrinking fraction year after year.
Sources:
youtube.com, iarc.who.int, cbc.ca, euronews.com, ici.radio-canada.ca, newsweek.com
